



Intercell AG: Changes to the Supervisory Board

Vienna (Austria), October 2, 2006

Michel Gréco was elected new chairman in Intercell's meeting of the supervisory board. He is taking over the function from **Ernst Günter Afting**, who in future will serve as Vice-chairman to Intercell's Supervisory Board.

Michel Gréco, who has been a member of Intercell's Supervisory Board since mid 2003, gained extensive experience of the vaccine industry through his previous positions in acknowledged vaccine companies. In his new role as chairman he will support the company in its next stage of growth.

Michel Gréco is serving as chairman or board member in a variety of supervisory boards of renowned companies and nonprofit organizations which are devoted to the development and commercialization of vaccines. Previously, Mr. Gréco was Deputy Chief Executive Officer of Aventis Pasteur S.A., now Sanofi Pasteur S.A.

Helmut Schühlsler, who represented the private equity firm TVM Capital on Intercell's Supervisory Board, resigns from his position.

The company would like to thank Helmut Schühlsler, who has been a member of the supervisory board for more than seven years, for his long-term commitment to the company and his outstanding support of Intercell on its way from a university spin-off to an internationally acknowledged vaccine player in the biotech arena.

The Supervisory Board of Intercell now includes the following members: Michel Gréco (Chairman), Ernst-Günter Afting (Vice-chairman), Staph Bakali, David Ebsworth, Hans Küpper, James Sulat and Hans Wigzell.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol



"ICLL".

For more information, please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.